智通财经APP讯，科伦博泰生物-B(06990)发布公告，本公司三款产品，即ADC Sacituzumab Tirumotecan(sac-TMT，亦称SKB264/MK-2870)(商品名：佳泰莱®)、西妥昔单抗N01注射液(前称A140)(商品名：达泰莱®)及Tagitanlimab(亦称A167)(商品名：科泰莱®)，已获纳入国家医疗保障局及中国人力资源和社会保障部于2025年12月7日公布的国家医保目录。值得注意的是，ADC Sacituzumab Tirumotecan有两项适应症获纳入国家医保目录。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.